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Background and Objectives: We compared the efficacy and safety of valsartan and rosuvastatin combination therapy with each treat-
ment alone in hypercholesterolemic hypertensive patients.
Subjects and Methods: Patients who met inclusion criteria were randomized to receive 1 of the following 2-month drug regimens: val-
sartan 160 mg plus rosuvastatin 20 mg, valsartan 160 mg plus placebo, or rosuvastatin 20 mg plus placebo. The primary efficacy variables 
were change in sitting diastolic blood pressure (sitDBP) and sitting systolic blood pressure (sitSBP), and percentage change in low-density 
lipoprotein-cholesterol (LDL-C) in the combination, valsartan, and rosuvastatin groups. Adverse events (AEs) during the study were ana-
lyzed.
Results: A total of 354 patients were screened and 123 of them were finally randomized. Changes of sitDBP by least squares mean (LSM) 
were -11.1, -7.2, and -3.6 mm Hg, respectively, and was greater in the combination, as compared to both valsartan (p=0.02) and rosuvastatin 
(p<0.001). Changes of sitSBP by LSM were -13.2, -10.8, and -4.9 mm Hg, and was greater in the combination, as compared to rosuvastatin 
(p=0.006) and not valsartan (p=0.42). Percentage changes of LDL-C by LSM were -52, -4, and -47% in each group, and was greater in the 
combination, as compared to valsartan (p<0.001), similar to rosuvastatin (p=0.16). Most AEs were mild and resolved by the end of the study.
Conclusion: Combination treatment with valsartan and rosuvastatin exhibited an additive blood pressure-lowering effect with accept-
able tolerability, as compared to valsartan monotherapy. Its lipid lowering effect was similar to rosuvatatin monotherapy. 
(Korean Circ J 2015;45(3):225-233)
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Introduction
Hypertension and hyperlipidemia are well known cardiovascular 
risk factors that commonly coexist in a single patient.1) Patients 
with multiple risk factors have higher cardiovascular risk than pa-
tients with single factor.2) Thus it is critical to comprehensively 
control multiple factors for reducing future cardiovascular events. 
Angiotensin receptor blockers (ARBs) reduce cardiovascular events 
as well as blood pressure (BP), and are currently recommended as 
first line therapy for hypertension control.3) Previous studies have 
shown up-regulation of angiotensin II type 1 receptor by high lev-
els of low-density lipoprotein-cholesterol (LDL-C),4) and low-densi-
ty lipoprotein oxidation in patients with hypertension.5) Thus, it 
might be reasonable to use ARB and lipid-lowering agents, partic-
ularly a statin, for effective control of these 2 risk factors. 
Valsartan, an ARB, has dose-dependent efficacy for lowering 
BP.6) Prior outcome studies have shown beneficial clinical effects 
of valsartan.7)8) Rosuvastatin is a strong efficacy statin, and the 
latest U.S. guideline recommends it for high intensive lipid-low-
ering therapy.9) It has low extra-hepatic tissue penetration, low 
potential for CYP3A4 interactions, and distinct advantage in sub-
stantial LDL-C lowering capacity.10) A few studies suggested that 
statins may improve vasodilation capacity of large artery, which 
can affect BP.11) Though clinical efficacy of ARB and statins for 
BP and LDL-C control have been studied before,12)13) no random-
ized clinical trial has examined combined valsartan and rosuvas-
tatin treatment. 
We investigated whether the combination of valsartan and rosuv-
astatin would show additional efficacy and acceptable safety, as 
compared to each component alone for patients with hypertension 
and hyperlipidemia. 
Subjects and Methods 
Study population 
Patients aged 20-80 years who had hypertension and hyperlip-
idemia were eligible for the study. At screening, patients who had 
been administered antihypertensive agents, or drug-naïve patients 
with sitting diastolic blood pressure (sitDBP) ≥90 mm Hg were in-
cluded. Patients who had coronary artery disease (CAD) or CAD 
equivalents, and were classified as high risk according to National 
Cholesterol Education Program- Adult Treatment Panel (NCEP-ATP) 
III guidelines,14) were included if sitDBP was ≥80 mm Hg. At ran-
domization, patients with sitDBP ≥90 mm Hg or high risk patients 
with sitDBP ≥80 mm Hg were finally enrolled and randomized into 
treatment groups.15) Lipid profile inclusion criteria included patients 
who had been administered lipid-modifying agents, or drug-naïve 
patients who satisfied one of following: LDL-C≥100 mg/dL in pa-
tients with CAD, or CAD risk equivalents; LDL-C≥130 mg/dL in pa-
tients with ≥2 risk factors; or LDL-C≥160 mg/dL in patients with 
≤1 cardiovascular risk factor. After therapeutic lifestyle change 
(TLC), patients who met the following criteria were randomized: 
≥100 mg/dL in patients with CAD or CAD risk equivalents; LDL-
C≥130 mg/dL in patients with ≥2 risk factors with 10-year risk of 
10-20%; LDL-C≥160 mg/dL in patients with ≤1 risk factor or ≥2 
risk factors with 10-year risk <10%. 
Exclusion criteria included sitting systolic blood pressure 
(sitSBP)≥180 mm Hg or sitDBP≥110 mm Hg (for the high risk 
group, sitSBP≥160 mm Hg or sitDBP≥100 mm Hg), LDL-C≥250 
mg/dL, or TG≥400 mg/dL at screening and randomization (week 
0); symptomatic orthostatic hypotension at screening (decrease 
in sitSBP≥20 mm Hg or decrease in sitDBP≥10 mm Hg); history 
of acute coronary syndrome within 6 months, percutaneous cor-
onary intervention or coronary artery bypass graft, severe heart 
failure (functional class III or IV), severe valve disease, clinically 
significant arrhythmias; or stroke or transient ischemic attack 
within the last 6 months. Patients with severe obesity (body mass 
index≥40 kg/m2); uncontrolled diabetes mellitus (Hemoglobin 
A1c≥9.0%); thyroid dysfunction (TSH≥1.5xupper limit of normal 
[ULN]); creatine kinase (CK) >2xULN; creatinine clearance <30 mL/
min; serum creatinine ≥2 mg/dL; alanine transaminase (ALT) or as-
partate aminotransferase (AST) ≥2xULN; potassium <3.5 mEq/L or 
>5.5 mEq/L were also excluded. 
Study design
This study was a multicenter, randomized, factorial, double-blind, 
double-dummy Phase Ⅲ trial to evaluate the efficacy and safety 
of combination treatment with valsartan 160 mg and rosuvastatin 
20 mg, as compared to each component alone in patients with hy-
pertension and hyperlipidemia. The protocol was approved by the 
local Institutional Review Boards, and all subjects gave written in-
formed consent at enrollment. The study was conducted in accor-
dance with Korean Good Clinical Practice guidelines and the Dec-
laration of Helsinki. This study was started on May 8th 2012 and 
finished on March 29th 2013.
Screening was conducted for patients who satisfied inclusion/
exclusion criteria. Subjects who were taking antihypertensive or 
lipid-modifying agents discontinued those medications. Subjects 
who passed the screening tests underwent 6-week-TLC. After eli-
gibility based on BP and lipid levels (week 0) was ascertained, sub-
jects were randomly assigned to 1 of 3 treatment groups: combi-
nation therapy (valsartan 160 mg+rosuvastatin 20 mg), valsartan 
(valsartan 160 mg+placebo), or rosuvastatin (rosuvastatin 20 
mg+placebo). Placebo was administrated during the treatment 
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period to maintain double blindness. Randomization was per-
formed by randomization tables prepared for each institution. Af-
ter randomization, a code was transferred to a code manager who 
maintains the code in a separate file and breaks it in an emergency. 
However, no breaking of the code occurred in this study.
Subjects visited at the beginning of the 0th, 4th, and 8th weeks 
during the 8-week treatment period. Efficacy and safety were as-
sessed at weeks 4 and 8. BP was measured by the same person at 
a regular time with a validated electronic sphygmomanometer 
(HEM-7080 IT, Omron Healthcare, Kyoto, Japan). Twelve hour (for 
patients without diabetes) or 8 hour (for patients with diabetes) 
fasting blood samples for lipid profile obtained during regular vis-
its were analyzed in the central laboratory. Double blind protocol 
was maintained during the treatment period. 
Major safety considerations leading to study treatment discon-
tinuation were: uncontrolled high BP (e.g., sitSBP≥200 mm Hg, sit-
DBP≥120 mm Hg) or hypotension (e.g., sitSBP <90 mm Hg, sitDBP 
<60 mm Hg); ALT and AST >3xULN; CK >5xULN at any time during 
the study period.
Outcome variables
Primary efficacy variables were change in sitDBP and sitSBP at 
week 8 for the combination and valsartan alone groups, and per-
centage change in LDL-C at week 8 for the combination and rosu-
vastatin alone groups. In addition, we analyzed changes of pulse 
pressure in each group. Secondary efficacy variables were propor-
tion of subjects achieving BP treatment target at weeks 4 and 8 
according to the European Society of Hypertension and European 
Society of Cardiology hypertension guideline (2003)15) and propor-
tion of subjects achieving the LDL-C target at week 4 and 8 ac-
cording to NCEP-ATP III guideline (2004).14) 
Safety was based on the number of patients experiencing any 
adverse event (AE), or serious AE. 
A serious AE refers to an AE that causes death or threatens life; 
causes short- or long-term hospitalization; causes permanent dis-
ability or reduction in function; causes congenital abnormality or a 
birth defect; or causes other medically important events. AEs and 
serious AEs were recorded at each study visit by history taking, 
physical examinations, and laboratory tests. The relationship of AEs 
to investigational products was evaluated. 
Statistical analysis 
The superiority of the combination therapy compared to each 
mono-therapy regarding changes of BP and LDL-C (change of sit-
DBP in the combination group vs. the rosuvastatin group and the 
% change of LDL-C in the combination group vs. the valsartan 
group) was tested in this study. For sample size calculation, 95% 
power was selected to each efficacy variable. Because two primary 
evaluation points needed to be proved at once, overall power be-
came 90.25% (0.95x0.95=0.9025). Thirty-three patients per treat-
ment group were needed to provide 95% power at a 2.5% confi-
dence level (2-tailed). Differences in sitDBP and LDL-C changes 
were based on prior studies that used valsartan and rosuvastatin 
and assumed as -6.9 mm Hg16) and -49.7 mg/dL,17) respectively. 
Calculated sample size for sitDBP was greater than that for LDL-C 
and this was finally determined as sample size accordingly. To con-
trol for an expected dropout rate of 20%, 42 subjects were 
planned for each group. The full efficacy analysis set consisted of 
patients who had ≥1 primary efficacy endpoints and had received 
test agents at least once. The safety set, used for safety analysis, 
consisted of subjects who received test agents at least once after 
randomization.
Continuous variables were presented as mean and standard de-
viation. Frequency and percentage were presented for categorical 
variables. A test was conducted to determine any difference in 
baseline data between treatment groups. Analysis of variance or 
Kruskal-Wallis tests were conducted for continuous variables. Chi- 
square or Fisher’s exact tests were conducted for categorical vari-
ables. The paired t-test was used to assess the difference in pa-
rameter before and after drug treatment within each group. 
Student’s t-test was used to compare the mean value of continu-
ous outcome variables between 2 groups. Analysis of covariance 
(ANCOVA) was conducted for the analysis of primary efficacy vari-
ables, with baseline levels as covariate. Outcome variables in the 
combination group were compared to those from the monothera-
py group with the least squares mean estimated by ANCOVA for 
sitDBP change, sitSBP change, and LDL-C percentage change. A 
2-tailed 95% confidence interval was calculated for the outcome 
variables. Prior to the ANCOVA, a test was performed for any inter-
action between the covariate and the treatment groups. If a signif-
icant interaction was present (p value<0.1), the corresponding co-
variate was excluded from the final ANCOVA model. All analyses 
were performed using SAS 9.2 (SAS Institute Inc., Cary, NC, USA).
Results
Study population
A total of 354 subjects from 23 institutions underwent screen-
ing, of whom 123 were randomized. 231 subjects were excluded 
after TLC. The number of exclusion before randomization was rela-
tively large and mainly due to improvement of LDL-C or BP after 
6-week TLC. One hundred and six and 74 subjects did not meet 
LDL-C level and BP, respectively. Thirty-four subjects declined to 
participate after submission of written consent. Of the randomized 
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subjects, 101 completed the study: 35 in the combination group, 
36 in the valsartan group, and 30 in the rosuvastatin group. Of the 
123 randomized subjects, 121 were included in the safety set, 
while 116 were included in the analysis set (Fig. 1). 
Characteristics of the subjects who were randomized were pre-
sented in Table 1. The mean age was 61.5 years and 68% were 
male. Most baseline variables were not different between groups. 
The mean sitDBP and mean LDL-C level of all subjects were 93±6 
mm Hg and 153±28 mg/dL respectively, and were similar in the 3 
groups (Table 1). Pulse pressure (p=0.04) showed significant 
(p=0.04), and sitSBP showed marginal difference (p=0.055) be-
tween the groups. The difference of sitSBP became significant in 
the full analysis set after a few subjects dropped out during the 
study. 
Primary efficacy variables
Changes in outcome variables at week 8 were presented in Table 2. 
SitDBP changes by least square mean (LSM) were -11.1, -7.2, and 
-3.6 mm Hg in each group, respectively, and was significantly 
greater in the combination group, as compared to both valsartan 
(p=0.02) and rosuvastatin groups (p<0.001). Changes of sitSBP by 
LSM were -13.2, -10.8, and -4.9 mm Hg, respectively, and was 
greater in the combination group vs. rosuvastatin group (p=0.006), 
but not compared to valsartan group (p=0.42) (Fig. 2A). Percentage 
change of LDL-C by LSM were -52, -4, and -47% in each group, 
and was greater in the combination group, as compared to the 
valsartan group (p<0.001), but not compared to rosuvastatin 
group (p=0.16). In addition, there was no significant difference in 
terms of change in pulse pressure between the combination and 
valsartan group. (-1.3 mm Hg vs. -4.4 mm Hg, respectively, p=0.31) 
(Supplementary Table 1 in the online-only Data Supplement).
Percentage changes of LDL-C were -53±12% in the combination 
group and -46±16% in the rosuvastatin group. The difference be-
tween the 2 groups was not significant before and after ANCOVA 
adjustment (Fig. 2B). In the valsartan group, LDL-C levels did not 
significantly change through the 8-week treatment (-4±19%, 
p=0.065) (Table 2). 
Secondary efficacy variables 
Proportion of subjects who achieved target BP at weeks 4 and 8 
were shown in Fig. 3A. Proportions at week 4 were not different 
between the combination and valsartan groups (41.5% vs. 32.5%, 
respectively, p=0.40). Proportion at week 8 was higher, as com-
pared to week 4 in the combination group without significance 
(51.2% vs. 35.0%, respectively, p=0.14).
Proportion of subjects who achieved target LDL-C level at weeks 
Enrollment
Allocation
Follow-up
Analysis
Assessed for eligibility (n=354)
Randomized (n=123)
Valsartan 160 mg+
placebo (n=41)
Valsartan 160 mg+
rosuvastatin 20 mg (n=43)
Lost to follow-up 
(n=0)
Lost to follow-up 
(n=0)
Lost to follow-up 
(n=2)
Analysed (n=35)
Excluded from analysis
(missing data) (n=2)
Analysed (n=40)
Excluded from analysis
(missing data) (n=1)
Analysed (n=41)
Excluded from analysis
(missing data) (n=2)
Rosuvastatin 20 mg+
placebo (n=39)
Excluded (n=231)
  Not meeting inclusion/exclusion criteria  
    (n=183)
  Declined to participate (n=34)
  Other reasons (n=14)
  Fig. 1. Subject disposition from enrollment to the end of the study. 
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4 and 8 were presented in Fig. 3B. Proportions at week 4 were sim-
ilar in the combination and rosuvastatin groups. At week 8, pro-
portion was marginally higher, but not significant, in the combina-
tion group, as compared to the rosuvastatin group (100% vs. 
91.4%, respectively, p=0.09). 
Safety variables
Ten (23%) in the combination group, 7 (17%) in the valsartan 
group, and 4 (11%) in the rosuvastatin group experienced AEs. 
Most AEs were mild and resolved at the end of the study (Table 3). 
Subjects who experienced AEs possibly related to test agents were: 1 
in the combination group (2.3%), 2 in the valsartan group (4.9%), and 
1 in the rosuvastatin group (2.7%). One subject in the combination 
group showed ALT and AST levels >3xULN at week 8, which returned 
to normal at follow-up. In addition, one in the valsartan group had 
CK level >3xULN at week 8, which became normal at follow-up. 
One serious AE was a patient admitted on a day of randomiza-
tion due to nausea and poor oral intake. However, this symptom 
was not likely to be associated with the test agents. In addition, 
they were both resolved after occurrence.
Discussion
Combination of valsartan 160 mg and rosuvastatin 20 mg re-
duced sitDBP more than valsartan 160 mg alone by week 8 of 
treatment. sitSBP reduction was not significantly different be-
tween the 2 groups. Percentage change of LDL-C was similar be-
tween the combination and rosuvastatin groups. Target BP and 
LDL-C achievement rates were higher in the combination group 
than each group alone without statistical significance. Treatment 
regimens were well-tolerated during the study. These results dem-
onstrated that this combination has an additive effect on BP low-
ering and is an appropriate therapeutic option for patients with 
hypertension and hyperlipidemia. 
Several reports demonstrated effects of statin on BP in animal 
studies. Lovastatin and pravastatin attenuated the onset and pro-
gression of hypertension and reduced proteinuria and glomerular 
injury.18)19) A few studies showed that statins significantly lowered 
BP, as compared to placebo in untreated hypertensive patients.12)20) 
The Brisighella Heart Study evaluated the effect of different lipid-
lowering strategies on BP.21) Subjects with total cholesterol ≥239 
mg/dL were treated with 1 of 4 lipid-lowering regimens: low-fat 
Table 1. Baseline characteristics of the study subjects
Combination
(n=43)
Valsartan
(n=41)
Rosuvastatin
(n=39) p
Age, years            61.3±8.5 62.6±8.2 60.2±11.1 0.59
Male   27 (63) 27 (66) 31 (80) 0.23
Medical history
Diabetes mellitus   5 (12)   7 (17)   8 (21) 0.54
Hypertension  37 (86) 39 (95) 34 (87) 0.35
Hyperlipidemia 36 (84) 33 (81) 31 (80) 0.87
Coronary artery disease 2 (5) 0 (0) 0 (0) 0.33
Body mass index, kg/m2 25.2±2.4  25.5±3.4  25.5±3.1 0.93
sitDBP, mm Hg 94±6  93±5  94±6 0.97
sitSBP, mm Hg 147±11 153±11  150±12 0.055
Pulse pressure, mm Hg   53.5±11.3      60±11.8 56.4±11 0.04
Fasting glucose, mg/dL 109±26 103±12   111±24 0.38
BUN, mg/dL 14.8±4.5 16.5±4.3  15.7±4.2 0.20
Creatinine, mg/dL   0.9±0.2   0.9±0.2    0.9±0.2 0.56
eGFR, mL/min/1.73 m2   81.9±20.3   85.7±20.7    83.1±18.2 0.77
Lipid profile 
Total cholesterol, mg/dL   239±36 230±35   226±32 0.20
TG, mg/dL   186±76 155±64     186±120 0.24
HDL-C, mg/dL   48±9   49±10    49±11 0.83
LDL-C, mg/dL   156±30 154±29  144±25 0.16
Values are mean±SD or number (%).; sitDBP: sitting diastolic blood pressure. sitSBP: sitting systolic blood pressure, BUN: blood urea nitrogen, eGFR: esti-
mate glomerular filtration rate, TG: triglyceride, HDL-C: high-density lipoprotein-cholesterol, LDL-C: low-density lipoprotein-cholesterol
230 Synergistic Effects of Valsartan and Rosuvastatin
http://dx.doi.org/10.4070/kcj.2015.45.3.225 www.e-kcj.org
diet, cholestyramine, gemfibrozil, or simvastatin. After 5 years of 
treatment, BP decreased only in the group with SBP ≥140 mm Hg, 
and was greater with simvastatin treatment. Conversely, BP did 
not decrease in the groups with lower baseline BP. This study sug-
gested that statins might improve BP control in subjects with both 
hypercholesterolemia and under-controlled hypertension.
Sposito et al.13) noted greater BP lowering with enalapril or lisin-
opril in a small group of patients treated with pravastatin or lovas-
tatin. A similar effect for simvastatin was reported in patients un-
der treatment with various antihypertensive medications.11)20) A 
retrospective analysis showed that effects of statin on BP were 
more obvious in patients treated with renin-angiotensin system 
blockades or calcium channel blockers.11) However, statins’ addi-
tional antihypertensive effects are sometimes inconsistent. In one 
study, patients who received simvastatin 20 mg or 80 mg plus val-
sartan 160 mg for 12 weeks did not have lower BP, as compared to 
those who assigned to valsartan 160 mg alone.22) In the present 
study, additional BP lowering was noted only for diastolic BP and 
not for systolic BP. Although the precise reason for this finding 
cannot be fully understood, it is plausible that marginally higher 
baseline sitSBP in the valsartan group might have influenced the 
results. A prior study demonstrated that statin shows BP lowering 
effect, particularly in under-controlled hypertension. Accordingly, 
in our study, the combination therapy could not have shown its 
additional BP lowering effect in sitSBP, because the baseline sitSBP 
was relatively lower in the combination group, as compared to the 
valsartan group. To adjust the baseline difference, we used ANCO-
VA for primary efficacy variables with baseline levels as covariate. 
Prior to ANCOVA, a test for interaction between the covariate and 
the treatment groups showed no interaction. In the manuscript, 
we presented the least-square mean change of the primary effica-
cy variables by ANCOVA.
In addition, the difference in target BP achievement rate between 
the 2 groups was not statistically significant. However, we cannot 
rule out a statistically greater BP lowering in the combination group 
with a study of a larger sample size. 
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The mechanism by which statins affect blood pressure is not 
clearly understood. One possibility is that statins’ antihypertensive 
effect is dependent on their ability to prevent renal vascular hy-
pertrophy. Another explanation is that statins improve endotheli-
um dependent vaso-relaxation,23) which was more prominent in a 
higer dose.24) Peripheral arterial compliance can be impaired in pa-
tients with high blood cholesterol levels, and this might affect 
BP.25) Statins improve vasodilatory capacity, and possibly increase 
artery compliance. In addition, it has been experimentally shown 
that statins may promote up-regulation of vascular nitric oxide 
synthase.26) This could contribute to modulation of peripheral vas-
cular tone, irrespective of reduction in circulating cholesterol lev-
els. An additional mechanism may be the capacity of statins to 
blunt vasoconstrictive and presser response to vascular agonists, 
such as angiotensin II or norepinephrine.27) Interestingly, all of 
these conditions might increase the sensitivity of the vessel wall to 
the vasodilating effect of medications such as angiotensin-con-
verting enzyme inhibitors or ARBs. Recently, several studies have 
shown that the combination of renin-angiotensin system block-
ades and statins had distinct vascular effects in hypertension with 
dyslipidemia. These studies demonstrated that this combination 
improves vascular function or metabolic phenotypes like adipo-
nectin levels or insulin sensitivity.28)29) 
To the best our knowledge, this randomized, double-blind study 
is the first to show the additive effect of valsartan and rosuvas-
tatin combination therapy on BP. Because these 2 agents are now 
popularly prescribed based on clinical evidence, our data further 
supports that this combination is a reasonable regimen. However, 
Table 2. Changes of blood pressure and LDL-C at week 8
Combination
(n=41)
Valsartan
(n=40)
Rosuvastatin
(n=35) p
* p†
sitDBP, mm Hg   
Before 94±7 93±5 94±6
After 83±10 86±8 90±8
Change -11.2±7.1 -7.2±7.2 -3.6±6.5
Change (LSM) -11.1 -7.2 -3.6 0.02 <0.001
p‡ <0.001 <0.001 0.002
sitSBP, mm Hg   
Before 146±11 153±11 150±12
After 134±15 141±15 145±15
Change -12.5±11.2 -11.6±14.4 -5.2±13.2
Change (LSM) -13.2 -10.8 -4.9 0.42 0.006
p‡ <0.001 <0.001 0.025
LDL-C, mg/dL   
Before 158±28 155±29 145±24
After 74±19 146±28 77±22
% change -53±12 -4±19 -46±16
% change (LSM) -52 -4 -47 <0.001 0.16
p‡ <0.001 0.065 <0.001
Values are mean±SD. *Comparison between combination vs. valsartan groups, †Comparison between combination vs. rosuvastatin groups, ‡Comparison in 
a group before and after treatment. LDL-C: low-density lipoprotein-cholesterol, sitDBP: sitting diastolic blood pressure, LSM: least squares mean, sitSBP: 
sitting systolic blood pressure
Table 3. Adverse event summary 
Combination
(n=43)
Valsartan
(n=41)
Rosuvastatin
(n=37) p
Any adverse events 15 11 7
Number of subjects who experienced AEs 10 (23.3 ) 7 (17.1 ) 4 (10.8 ) 0.34
Number of subjects who experienced SAEs 1 (2.3 ) 0 (0 ) 0 (0 ) 1.00
AE: adverse event, SAE: serious adverse event
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this study had a relatively small sample size and was conducted 
over a short period of time. Thus, further clinical studies over a 
longer period are needed to confirm this combination’s clinical 
benefit. It was beyond the scope of the current study to explore 
potential mechanisms of the 2 agents’ additive effect. Further 
studies on the biological mechanisms, such as vascular function, 
might be helpful in understanding our results. The randomization 
process was strictly conducted in our study with the support of a 
statistics specialist. However, marginal imbalance in the baseline 
characteristics seemed to occur by chance. Imbalance in the base-
line characteristics is known to occur even in qualified randomized 
trials. Moreover, such imbalance reportedly does not affect the in-
ternal validity of studies.30) 
This study found greater BP reduction in combination of valsar-
tan 160 mg and rosuvastatin 20 mg than valsartan 160 mg, and 
comparable LDL-C lowering to rosuvastatin 20 mg. This result indi-
cated that a combination of these 2 agents might be a reasonable 
therapeutic option for patients with hypertension and hyperlipid-
emia. 
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Supplementary Table 1. Changes of pulse pressure and fasting glucose level at week 8
Combination
(n=41)
Valsartan
(n=40)
Rosuvastatin
(n=35)
Pulse pressure, mm Hg    
Before   52.6±10.2   60±11.9  56.6±10.9
After   51.2±12.5 55.6±11.6   55.0±11.9 
Change -1.3±9.2  -4.4±10.9 -1.6±9.4 
p 0.21 0.01 0.32
Fasting glucose, mg/dL 
Before 109±27 103±12 112±24
After 115±56 104±14 109±25
% change    5.6±42.1    1.5±10.8   -2.8±14.1
p 0.13 0.37 0.25 
Values are mean±SD.
